The launch of Heme Libra, a 28-day hemophilia treatment, revealed a key challenge: patients accustomed to daily infusions were scared to trust the new, infrequent therapy. This shows that marketing truly disruptive products requires building trust and overcoming ingrained user habits, going beyond just demonstrating clinical superiority.

Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

Focus groups and surveys are biased by pre-set questions. Ethnographic research—observing patients in their daily lives—uncovers their true hopes and needs, which can fundamentally transform a drug's development and go-to-market strategy.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

Successful drug launches hinge on executional excellence, which is driven by soft skills like listening, effective communication, and building cross-functional alignment. Analytical strategy alone is insufficient if it cannot be translated into action by the team on the ground.

Successful execution of a pharmaceutical launch strategy relies more on soft skills like communication, listening, and team alignment than on purely analytical skills. These behavioral skills are essential for creating cohesive cross-functional teams and ensuring buy-in from those executing the plan.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

A common clinical need doesn't mean a one-size-fits-all commercial strategy. To scale globally, companies must appreciate the technical, clinical, and commercial differences in each healthcare system and invest in local resources to navigate them successfully.